Survival of patients with skin melanoma in Europe increases further: Results of the EUROCARE-5 study
Survival of patients with skin melanoma in Europe increases further: Results of the EUROCARE-5 study
复制标题
DOI：
10.1016/j.ejca.2015.07.039
复制
发表时间：
2015-10-01
影响因子：
8.4
通讯作者：
Eisemann, Nora
中科院分区：
文献类型：
--
作者：
Crocetti, Emanuele;Mallone, Sandra;Eisemann, Nora
背景：在欧洲，皮肤黑色素瘤（SM）的生存率随着时间的推移而增加。目的是评估最近的趋势和国家和地区之间的差异European.Methods：相对生存率（RS）估计和地理比较的基础上，241,485例患者年龄在15岁及以上的诊断侵入性SM在欧洲（2000-2007年）。使用周期法估计了1999-2007年期间213，101例患者的生存时间趋势。年龄，性别，子网站和形态subgroupsconsidered.Results：在欧洲患者，估计5年RS为83%（95%置信区间，CI 83-84%）。居住在北方（88%; 87-88%）和中欧（88%; 87- 88%）的患者的数值最高，其次是爱尔兰和英国（UK）（86%; 85-86%）和南欧（83%; 82-83%）。东欧的存活率最低（74%; 74-75%）。在各区域内，国家间斯普斯卡共和国百分比的绝对差异从4%（北部）到34%（东部）不等。RS随年龄增长而明显降低，女性高于男性。根据SM形态和皮肤亚部位的差异也出现了。从1999年到2007年，生存率略有增加，北方略有改善，东欧改善最明显。北方和南方国家，特别是东欧国家之间的差距虽然仍然存在，但随着时间的推移而缩小。诊断时分期分布的差异可以解释大部分的地理差异。然而，生存率的改善部分可归因于早期诊断实践的过度诊断。(C)2015爱思唯尔有限公司版权所有。
Background: In Europe skin melanoma (SM) survival has increased over time. The aims were to evaluate recent trends and differences between countries and regions of Europe.Methods: Relative survival (RS) estimates and geographical comparisons were based on 241,485 patients aged 15 years and over with a diagnosis of invasive SM in Europe (2000-2007). Survival time trends during 1999-2007 were estimated using the period approach, for 213,101 patients. Age, gender, sub-sites and morphology subgroups were considered.Results: In European patients, estimated 5-year RS was 83% (95% confidence interval, CI 83-84%). The highest values were found for patients resident in Northern (88%; 87-88%) and Central (88%; 87-88%) Europe, followed by Ireland and United Kingdom (UK) (86%; 85-86%) and Southern Europe (83%; 82-83%). The lowest survival was in Eastern Europe (74%; 74-75%). Within regions the intercountry absolute difference in percentage points of RS varied from 4% (North) to 34% (East). RS decreased markedly with patients' age and was higher in women than men. Differences according to SM morphology and skin sub-sites also emerged. Survival has slightly increased from 1999 to 2007, with a small improvement in Northern and the most pronounced improvement in Eastern Europe.Discussion: SM survival is high and still increasing in European patients. The gap between Northern and Southern and especially Eastern European countries, although still present, diminished over time. Differences in stage distribution at diagnosis may explain most of the geographical differences. However, part of the improvement in survival may be attributed to overdiagnosis from early diagnosis practices. (C) 2015 Elsevier Ltd. All rights reserved.